[Cannabinoid and cathinone designer drugs - the workings and selected methods of analysis]. / Dopalacze z grupy kannabinoidów i katynonów ­ dzialanie oraz wybrane metody analizy.

Recently, there has been an increase in the consumption of designer drugs, substances aimed at producing psychoactive, energizing, euphoric or anesthetic effects. Designer drugs are substitutes of actual narcotics, whose possession is banned under Polish law according to the Act of 29 July 2005. The latest reports suggest that the number of synthetic psychoactive substances is increasing. In the span of 2012, a total of 28 new synthetic cannabinoids were discovered in member states of the European Union. Synthetic psychoactive substances appear in different forms on the market: tablets (often very colourful and interestingly-shaped), seeds, dried product (sprayed with synthetic substance and redried), crystals or powder. The way of application is greatly diverse, and depends on the form in which a drug is produced and dispensed. The methods of intoxication include smoke inhalation (oftentimes blends are smoked), intranasal or oral application, placing crystals on the eye, or injection. Said methods correspond, with varying degrees, to invoking different psychotic effects, such as agitation, panic attacks, paranoia, hallucinations, overall irritation, and aggression. Various cardiovascular effects, such as tachycardia or increase in blood pressure, may follow as well. However, the primary influence is on the nervous system, inhibiting the reuptake of neurotransmitters such as serotonin, noradrenalin and dopamine, and leading to their increased concentration at the presynaptic cleft, which in turn causes feelings of agitation and pleasure. The knowledge regarding the strength, toxicity, and metabolism of designer drugs is yet sparse. The same pertains to the knowledge regarding the handling of overdose cases.

[Fatal poisoning of pentedron ­ cases reports].

The issue of sudden deaths due to acute pentedron poisoning is presented in the report. The analysis included three cases autopsied. Biological material were delivered to the Toxicological Laboratory ToxLab placed in Katowice, during the autopsy were subjected to chemical-toxicological analysis. Analysis of blood samples in the first case present concentration of the pentedrone were 385 ng/ml, and present the concentration of delta- 9-tetrahydrocannabinol were 2.6 ng/ml. Analysis of blood and urine samples in the next case present pentedrone concentrations were 280 ng/ml i 255 ng/ml. Analysis of blood samples in the third case present concentration of the pentedrone were 340 ng/ml.